Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704

Soham D. Puvvada, Patrick J. Stiff, Michael Leblanc, James R. Cook, Stephen Couban, John P. Leonard, Brad Kahl, Deborah Marcellus, Thomas C. Shea, Jane N. Winter, Hongli Li, Lisa Rimsza, Jonathan W. Friedberg, Sonali M. Smith

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

Original languageEnglish (US)
Pages (from-to)686-691
Number of pages6
JournalBritish Journal of Haematology
Volume174
Issue number5
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Vincristine
Prednisolone
Doxorubicin
Cyclophosphamide
Lymphoma
Stem Cells
Transplants
Proteins
Immunohistochemistry
Rituximab

Keywords

  • autologous stem cell transplant
  • BCL2
  • double hit lymphoma
  • double protein lymphoma
  • MYC

ASJC Scopus subject areas

  • Hematology

Cite this

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant : subset analysis of randomized trial intergroup SWOG S9704. / Puvvada, Soham D.; Stiff, Patrick J.; Leblanc, Michael; Cook, James R.; Couban, Stephen; Leonard, John P.; Kahl, Brad; Marcellus, Deborah; Shea, Thomas C.; Winter, Jane N.; Li, Hongli; Rimsza, Lisa; Friedberg, Jonathan W.; Smith, Sonali M.

In: British Journal of Haematology, Vol. 174, No. 5, 01.09.2016, p. 686-691.

Research output: Contribution to journalArticle

Puvvada, SD, Stiff, PJ, Leblanc, M, Cook, JR, Couban, S, Leonard, JP, Kahl, B, Marcellus, D, Shea, TC, Winter, JN, Li, H, Rimsza, L, Friedberg, JW & Smith, SM 2016, 'Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704', British Journal of Haematology, vol. 174, no. 5, pp. 686-691. https://doi.org/10.1111/bjh.14100
Puvvada, Soham D. ; Stiff, Patrick J. ; Leblanc, Michael ; Cook, James R. ; Couban, Stephen ; Leonard, John P. ; Kahl, Brad ; Marcellus, Deborah ; Shea, Thomas C. ; Winter, Jane N. ; Li, Hongli ; Rimsza, Lisa ; Friedberg, Jonathan W. ; Smith, Sonali M. / Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant : subset analysis of randomized trial intergroup SWOG S9704. In: British Journal of Haematology. 2016 ; Vol. 174, No. 5. pp. 686-691.
@article{5d06cc5d65774bdbbdf7a3437b372877,
title = "Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704",
abstract = "Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6{\%}) with MYC overexpression; 20 (74{\%}) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.",
keywords = "autologous stem cell transplant, BCL2, double hit lymphoma, double protein lymphoma, MYC",
author = "Puvvada, {Soham D.} and Stiff, {Patrick J.} and Michael Leblanc and Cook, {James R.} and Stephen Couban and Leonard, {John P.} and Brad Kahl and Deborah Marcellus and Shea, {Thomas C.} and Winter, {Jane N.} and Hongli Li and Lisa Rimsza and Friedberg, {Jonathan W.} and Smith, {Sonali M.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/bjh.14100",
language = "English (US)",
volume = "174",
pages = "686--691",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant

T2 - subset analysis of randomized trial intergroup SWOG S9704

AU - Puvvada, Soham D.

AU - Stiff, Patrick J.

AU - Leblanc, Michael

AU - Cook, James R.

AU - Couban, Stephen

AU - Leonard, John P.

AU - Kahl, Brad

AU - Marcellus, Deborah

AU - Shea, Thomas C.

AU - Winter, Jane N.

AU - Li, Hongli

AU - Rimsza, Lisa

AU - Friedberg, Jonathan W.

AU - Smith, Sonali M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

AB - Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.

KW - autologous stem cell transplant

KW - BCL2

KW - double hit lymphoma

KW - double protein lymphoma

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=84987735570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987735570&partnerID=8YFLogxK

U2 - 10.1111/bjh.14100

DO - 10.1111/bjh.14100

M3 - Article

C2 - 27072903

AN - SCOPUS:84987735570

VL - 174

SP - 686

EP - 691

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -